L’Oréal has signed an agreement to acquire a majority stake in British skincare brand Medik8, continuing its push into the premium skincare market. The move strengthens L’Oréal’s Luxe division and expands its footprint in the UK and U.S. Here's what you need to know:
- L’Oréal announced it will acquire a majority share in Medik8, a UK-based premium skincare brand, with the deal expected to close in the coming months.
- The brand will become part of the L’Oréal Luxe portfolio, which includes Lancôme and Kiehl’s, and is expected to drive growth, especially in the U.S. market.
- Medik8’s founder and leadership team will remain to ensure continuity, while previous investor Inflexion retains a minority stake with buyout options secured by L’Oréal.
- Medik8 reported GBP 45.3 million in sales for FY 2023 and is known for high-efficacy skincare at accessible prices, aligning well with L’Oréal’s premium growth strategy.
- The acquisition follows L’Oréal’s purchase of Aesop in 2023.
L’Oréal and Medik8: Growth and Success
L’Oréal’s stake in Medik8 boosts its premium skincare portfolio and expands reach in the UK and U.S. markets. Here’s how both DTC brands stack up based on Charm Growth Score, Charm Success Score, and other key metrics.
L’Oréal
Charm Growth Score: 74.99
Charm Success Score: 79.62
Fastest-Growing Channel: Facebook
A global beauty leader offering innovative skincare, haircare, and cosmetics across luxury, professional, and mass-market segments.
Medik8
Charm Growth Score: 64.15
Charm Success Score: 49.42
Fastest-Growing Channel: Facebook
A science-led British skincare brand known for high-performance formulas focused on anti-aging and skin health, rooted in clean, clinical innovation.
Want more ecommerce insights like these to help you source and diligence your next investment opportunity? Request a demo with Charm today.
Questions about Charm?
Attend our monthly Charm webinar where our Customer Success Managers will show you how Charm can help you grow your business.
Sign up for the Webinar